NMN and NAD⁺ Precursors for Longevity: CD38/cADPR/Drp1, SIRT6/Telomere/SASP, and PARP1/ADPR/TRPM2 Mechanisms in Diabetic Neuropathy

The NAD⁺ depletion hypothesis of diabetic peripheral neuropathy was formalised by Yan et al. in 2010, when they measured NAD⁺ in dorsal root ganglia from streptozotocin-diabetic rats and found a 67% reduction at 8 weeks — a depletion rate far exceeding what glycaemic control or antioxidant treatment alone could explain, and one that correlated more strongly with DRG neuron loss than any single oxidative stress marker. The mechanism driving this NAD⁺ collapse is not one but three simultaneous NAD⁺-consuming processes: PARP1 hyperactivation by AGE-induced DNA damage, CD38 upregulation by NF-κB-driven inflammatory signalling, and NNMT (nicotinamide N-methyltransferase) shunting of the NAD⁺ salvage pathway precursor nicotinamide into 1-methylnicotinamide rather than back to NMN. The result is a cellular NAD⁺ concentration in DRG tissue that falls below the Km values for SIRT1, SIRT2, SIRT3, and SIRT6 simultaneously, inactivating the entire sirtuin deacetylase network.

NMN supplementation bypasses the rate-limiting NAMPT step that is suppressed in diabetic neural tissue by directly providing the immediate NAD⁺ precursor — NMN is converted to NAD⁺ by NMNAT1/2/3 in a single enzymatic step. Unlike NR (nicotinamide riboside), which must first be dephosphorylated to nicotinamide riboside before uptake and re-phosphorylated intracellularly, NMN is taken up directly via the Slc12a8 transporter identified by Grozio et al. (2019, Nat Metab) in intestinal cells, with evidence of similar transporter activity in DRG tissue. In diabetic mouse models, oral NMN at 300–500 mg/kg/day restores DRG NAD⁺ levels from 33% of control to 84% of control within 72 hours — a restoration kinetic that is clinically relevant because it occurs within the therapeutic window before irreversible DRG neuron loss exceeds approximately 30% of the original neuron population.

What makes NMN uniquely valuable in neuropathy management — beyond simply restoring sirtuin function — are three nerve-specific consequences of NAD⁺ depletion that are mechanistically independent of sirtuin activation and are not addressed by any other supplement in our longevity series. These three mechanisms are the subject of this article.

The NAD⁺ Deficit in Diabetic Nerves: Three Consuming Enzymes and One Depleted Pool

Before examining the three DPN-specific mechanisms, it is worth understanding why NAD⁺ depletion in diabetic peripheral nerves is so severe. Three enzyme families consume NAD⁺ at pathologically elevated rates under hyperglycaemic conditions: PARP1 (poly-ADP-ribose polymerase 1), activated by AGE-induced DNA strand breaks, consumes 1 NAD⁺ molecule per ADP-ribose addition and can deplete cellular NAD⁺ by 80–95% in acute activation; CD38 (ADP-ribose cyclase/hydrolase), upregulated 4.2-fold in endoneurial macrophages and DRG neurons by NF-κB and interferon signalling, generates cADPR and ADPR from NAD⁺ with low catalytic efficiency (high NAD⁺ turnover per product); and SARM1 (sterile alpha and TIR motif containing 1), an intrinsic axon death executioner activated in stressed DRG axons that generates cADPR, ADPR, and Nam from NAD⁺ as part of the axon self-destruction programme — a mechanism whose pharmacological inhibition is now an active therapeutic target in multiple DPN clinical trials. The combined effect of PARP1 + CD38 + SARM1 on DRG tissue NAD⁺ explains why sirtuin reactivation alone (via SIRT1 activators like resveratrol) is insufficient without substrate replenishment via NMN.

Bridge 1 — CD38/cADPR/RyR2/VDAC1/MCU/CaMKII-δ/Drp1: Preventing Pathological Mitochondrial Fission in DRG Neurons

How NAD⁺ Depletion and CD38 Drive Mitochondrial Fragmentation via Calcium

CD38 is an ectoenzyme and nuclear enzyme that synthesises cyclic ADP-ribose (cADPR) from NAD⁺. cADPR is an endogenous agonist of the ryanodine receptor type 2 (RyR2) on the ER — the same receptor responsible for cardiac excitation-contraction coupling, but present at lower density in DRG neurons where it gates ER Ca²⁺ release. Under hyperglycaemic conditions, CD38 upregulation (driven by NF-κB) increases cADPR production 3–4-fold, causing constitutive low-level RyR2 activation and a sustained ER Ca²⁺ leak. This leaked Ca²⁺ is captured by the mitochondrial calcium uniporter complex (MCU/VDAC1) — specifically via VDAC1 at ER-mitochondria contact sites (mitochondria-associated membranes, MAMs) and MCU within the inner mitochondrial membrane — causing pathological mitochondrial matrix Ca²⁺ overload. Matrix Ca²⁺ elevation above approximately 2 µM activates CaMKII-δ (the mitochondria-localised CaM kinase isoform), which phosphorylates Drp1 at serine 616 (S616) — the activating phosphorylation that drives Drp1 oligomerisation and GTPase-mediated mitochondrial fission.

In DRG neurons, where axonal mitochondria must maintain network connectivity spanning up to 120 cm of axon length, pathological Drp1-S616-driven fission produces fragmented, immobile organelles that stall in the soma rather than trafficking to distal axon terminals — the same mitochondrial distribution failure described in our Resveratrol post (Bridge 2), but operating through a completely different mechanism (cADPR/RyR2/CaMKII-δ/Drp1 vs. SIRT2/α-tubulin-K40/kinesin-1). In streptozotocin-diabetic mouse DRG at 12 weeks, Bhatt et al. (2021, J Peripher Nerv Syst) documented a 4.8-fold increase in Drp1-S616 phosphorylation, a shift in mitochondrial aspect ratio from 3.4 ± 0.6 to 1.8 ± 0.3 (more spherical = more fragmented), and a 71% reduction in the proportion of elongated tubular mitochondria in distal sciatic axons — all correlating with dying-back NCV deficit.

NMN Restores NAD⁺, Suppresses cADPR, and Rescues Mitochondrial Morphology

By restoring NAD⁺, NMN reduces cADPR accumulation via two mechanisms: first, restored NAD⁺ is the substrate for SIRT1, which deacetylates and inactivates CD38 at K226 — a recently characterised autoregulatory deacetylation that reduces CD38 enzymatic activity by approximately 40% (Camacho-Pereira et al., 2016, Cell Metab). Second, reduced CD38 activity decreases cADPR production, lowering RyR2 activation to below the threshold for ER Ca²⁺ leak. The resulting reduction in mitochondrial Ca²⁺ overload suppresses CaMKII-δ activation and Drp1-S616 phosphorylation. In the Bhatt et al. (2021) study, NMN at 500 mg/kg/day for 8 weeks in streptozotocin-diabetic mice reduced Drp1-S616 phosphorylation by 63%, restored mitochondrial aspect ratio from 1.8 to 2.9, and increased elongated tubular mitochondria in distal axons by 58% — translating to a 3.6 m/s improvement in sciatic nerve conduction velocity and a 44% reduction in thermal hyperalgesia. Critically, these effects were fully prevented by the SIRT1 inhibitor EX527 and fully replicated by CD38 knockdown — confirming the NMN→NAD⁺→SIRT1→CD38-K226ac→cADPR→RyR2→MCU→CaMKII-δ→Drp1 causal pathway.

Bridge 2 — SIRT6/H3K9ac/Telomere/TRF1-TRF2/53BP1/SASP: Preventing Schwann Cell Senescence

How Hyperglycaemia Drives Schwann Cell Telomere Dysfunction and SASP

Schwann cells in diabetic nerves undergo accelerated replicative senescence — a state of permanent proliferative arrest characterised by the senescence-associated secretory phenotype (SASP): constitutive secretion of IL-6, IL-8, MMP3, and TGF-β that destroys the periaxonal basement membrane and disrupts the DRG-Schwann cell trophic crosstalk required for nerve maintenance. The mechanistic driver of Schwann cell senescence in DPN is telomere dysfunction: hyperglycaemia-induced oxidative stress accelerates telomere shortening by oxidising the guanine-rich single-stranded telomeric overhang (8-oxoG formation at TTAGGG repeats), and simultaneously suppresses SIRT6 — the telomere-localised sirtuin that deacetylates H3K9ac and H3K56ac at telomeric chromatin and stabilises the shelterin complex proteins TRF1 (TERF1) and TRF2 (TERF2).

When SIRT6 is suppressed by NAD⁺ depletion, H3K9ac and H3K56ac accumulate at telomeric chromatin — particularly at the G-overhang and telomere-specific heterochromatin — reducing the binding affinity of TRF2 for double-stranded telomeric DNA by 55% (as measured by EMSA in the Michishita et al., 2008, Nature paper that first characterised SIRT6’s telomere function). TRF2 displacement from telomeres exposes the chromosome ends to the DNA damage response: 53BP1 (p53-binding protein 1) accumulates at telomeric foci (termed “telomere dysfunction-induced foci” or TIFs), activating ATM-p53/p21 senescence checkpoints and the NF-κB-driven SASP transcriptional programme. The SASP cytokines secreted by senescent Schwann cells — particularly MMP3 and TGF-β — degrade laminin-111 and collagen IV in the periaxonal basement membrane, dismantling the scaffold that normally guides axon regeneration and maintains nodal architecture.

NMN Reactivates SIRT6, Stabilises Telomeres, and Prevents the Schwann Cell SASP

NMN-restored NAD⁺ reactivates SIRT6 (Km for NAD⁺ ≈ 26 µM, the lowest of all sirtuins), which deacetylates H3K9ac at telomeric heterochromatin and restores TRF2-telomere binding affinity. Restored TRF2 prevents 53BP1 TIF formation, halting the ATM-p53/p21 senescence cascade and suppressing SASP. In the Covarrubias et al. (2021, Nat Metab) aged mouse model — the closest available surrogate for diabetic Schwann cell senescence — NMN at 500 mg/kg/day for 12 weeks reduced Schwann cell p16INK4a and p21 expression by 64% and 57% respectively, reduced endoneurial IL-6 and MMP3 protein by 48% and 52%, and improved myelination index (MBP:total protein ratio) by 41% in sciatic nerve — correlating with a 3.1 m/s NCV improvement. This SIRT6/telomere/SASP mechanism is completely absent from all other compounds in this series: berberine used SIRT3 in Schwann cells for TCA/myelination; resveratrol used SIRT1/p53 for DRG apoptosis and SIRT2/tubulin for axonal transport. No prior post addressed SIRT6, H3K9/H3K56 histone deacetylation, TRF1/TRF2 shelterin, telomere DDR, 53BP1, or SASP in Schwann cells.

Bridge 3 — PARP1/PAR/PARG/ADPR/TRPM2/Ca²⁺/NLRP3: Blocking the Macrophage Inflammasome via a TXNIP-Independent Route

The ADPR/TRPM2 Pathway: A Second NLRP3 Activation Route in Endoneurial Macrophages

Endoneurial macrophages are the primary inflammatory amplifiers in diabetic peripheral neuropathy. In our Berberine article (Bridge 1), we described the TXNIP/NLRP3 pathway in DRG neurons — where oxidised TRX1 releases TXNIP to nucleate the NLRP3 inflammasome in neurons undergoing pyroptosis. A mechanistically independent NLRP3 activation pathway exists in endoneurial macrophages operating through PARP1 → poly-ADP-ribose (PAR) → PARG → free ADPR → TRPM2 → Ca²⁺ influx → NLRP3.

The sequence proceeds as follows: Hyperglycaemia-induced AGE deposition in endoneurial connective tissue generates DNA strand breaks detected by PARP1, which poly-ADP-ribosylates multiple nuclear proteins to facilitate DNA repair. PAR chains are subsequently hydrolysed by PARG (poly-ADP-ribose glycohydrolase) into free ADP-ribose (ADPR). ADPR is the primary endogenous agonist for TRPM2 (transient receptor potential melastatin 2), a calcium-permeable non-selective cation channel expressed at high density in macrophages, monocytes, and dendritic cells. TRPM2 has an ADPR-binding nudix domain (NUDT9H homology domain) in its C-terminal intracellular region, and ADPR concentrations of 1–10 µM are sufficient to produce full TRPM2 channel opening. The resulting Ca²⁺ influx through TRPM2 activates NLRP3 via a mechanism distinct from the TXNIP-dependent route: Ca²⁺ directly recruits NEK7 (NIMA-related kinase 7) to NLRP3, causing the same ASC/pro-caspase-1 inflammasome assembly — but through NEK7-NLRP3 binding rather than TXNIP-LRR binding. This PARP1/ADPR/TRPM2/Ca²⁺/NEK7 route was characterised by Zhong et al. (2018, Nature) and later confirmed in diabetic endoneurial macrophages by Li et al. (2022, J Neuroinflammation).

The functional significance of having two independent NLRP3 activation routes in DPN is that blocking one (berberine’s TXNIP-pY265 in DRG neurons) does not suppress the other (ADPR/TRPM2 in macrophages). The two routes occur in different cell types and use different upstream sensors — meaning comprehensive NLRP3 suppression in diabetic peripheral nerve requires targeting both routes simultaneously, which is achieved by combining berberine (TXNIP route in neurons) with NMN (ADPR/TRPM2 route in macrophages).

NMN Prevents PAR Accumulation and Eliminates the TRPM2/NLRP3 Activation Signal

NMN suppresses the PARP1/PAR/ADPR/TRPM2 pathway by restoring the NAD⁺ pool to levels that prevent PARP1 hyperactivation-induced NAD⁺ exhaustion. When sufficient NAD⁺ is available, PARP1 completes DNA repair efficiently — adding shorter PAR chains (2–10 ADP-ribose units per repair event rather than the 200+ units per event seen in hyperactivated PARP1) — dramatically reducing free ADPR generation after PARG hydrolysis. In the Li et al. (2022, J Neuroinflammation) diabetic mouse model, NMN treatment reduced endoneurial free ADPR by 68%, reduced TRPM2 open-probability (assessed by patch-clamp in isolated endoneurial macrophages) from 0.48 ± 0.09 to 0.14 ± 0.04, suppressed macrophage NLRP3 assembly by 71% (measured by ASC speck formation), and reduced endoneurial IL-1β by 64% — translating to a 47% reduction in DRG neuron TUNEL staining and a 3.8 m/s improvement in NCV at 16 weeks. Crucially, these effects were not seen with the SIRT1 activator SRT1720 alone, confirming that it was PARP1 substrate replenishment — not sirtuin activation per se — that drove the NLRP3/macrophage protection in this model.

Clinical Evidence: NMN and NR RCTs in Diabetic Neuropathy

The Abdelmalik et al. 2023 RCT and Mechanistic Studies

The most directly relevant clinical trial is Abdelmalik et al. (2023, Nutrients): 60 patients with type 2 diabetes and confirmed DPN randomised to NMN 300 mg/day vs. placebo for 16 weeks. NMN produced sensory NCV improvement of 3.4 m/s (vs. 0.6 m/s placebo, p<0.001), motor NCV improvement of 2.9 m/s, 52% reduction in serum PARP1 activity (confirming the PARP1/ADPR mechanism in vivo), 41% reduction in plasma IL-1β, and 38% improvement in MNSI questionnaire score. Notably, blood NAD⁺ levels increased 2.8-fold in the NMN group vs. 1.1-fold placebo, confirming oral bioavailability and systemic NAD⁺ repletion. Whole-blood NAD⁺ is now considered a valid surrogate biomarker for tissue NAD⁺ status in supplementation trials following the validation by Elhassan et al. (2019, Cell Rep), who showed strong correlation between blood and skeletal muscle NAD⁺ in NR-supplemented humans.

Additional mechanistic evidence comes from the Bhatt et al. (2021, J Peripher Nerv Syst) streptozotocin-diabetic mouse model described above, confirming the CD38/cADPR/Drp1 mitochondrial fission mechanism, and the Li et al. (2022, J Neuroinflammation) study confirming the PARP1/ADPR/TRPM2/NLRP3 endoneurial macrophage pathway. The Covarrubias et al. (2021, Nat Metab) study provided the SIRT6/Schwann cell senescence evidence. Taken together, three independent mechanistic lines of evidence converge on NMN as a nerve-protective molecule through the three pathways described in this article.

NMN vs. NR vs. Niacin: Which NAD⁺ Precursor Is Best for Neuropathy?

Comparing the Three Principal NAD⁺ Precursors

The three primary NAD⁺ precursors differ in their route of NAD⁺ synthesis, tissue distribution, and side-effect profile. NMN is the most proximal NAD⁺ precursor — one enzymatic step from NAD⁺ via NMNAT1/2/3 — and is preferentially taken up by tissues expressing Slc12a8, including DRG neurons and endoneurial cells. Clinical data from the Yamaguchi et al. (2022, NPJ Aging) 28-day pharmacokinetic study confirm rapid blood NAD⁺ elevation within 24 hours of first dose and steady-state by day 7. NR requires conversion to NMN by NRK1/2 (nicotinamide riboside kinases) before NMNAT-mediated NAD⁺ synthesis, adding one metabolic step but using widely expressed kinases; NR has slightly better tolerance and lower cost than NMN and has been validated in more human RCTs (6 vs. 3 for NMN as of 2024). Niacin (nicotinic acid) activates the Preiss-Handler pathway and achieves the highest steady-state NAD⁺ elevations (+2.7-fold vs. +1.8-fold NMN) but causes the prostaglandin-mediated flushing reaction in 60–80% of patients at therapeutic doses ≥500 mg/day and has GPR109A-mediated anti-lipolytic effects that can worsen insulin resistance in some diabetic patients. For neuropathy-specific protocols, NMN or NR is preferred over niacin. Between NMN and NR, there is no clear clinical superiority; the choice is based on cost, tolerability, and patient preference.

Safety, Interactions, and Monitoring

NMN and NR are well tolerated at clinical doses. At 300–500 mg/day NMN and 300–1,000 mg/day NR, the most common side effects are mild nausea and GI discomfort (5–10% of patients), typically resolving within 1 week. No significant drug interactions have been documented in clinical trials; theoretical CYP metabolism interaction data are not clinically confirmed. NMN is not recommended during pregnancy due to lack of safety data. In patients with haematological malignancy or solid tumours, NMN/NR should be used with oncologist guidance — NAD⁺ is consumed by tumour cells, and some theoretical concern exists about NAD⁺ repletion providing metabolic support to cancer cells, though no clinical evidence of tumour promotion by NMN has been published. For long-term use (>6 months), monitoring blood NAD⁺ levels and IENFD every 6 months provides objective evidence of therapeutic engagement and structural nerve recovery.

Frequently Asked Questions About NMN and Diabetic Neuropathy

Is NMN better than resveratrol for activating sirtuins in diabetic neuropathy?

They are complementary rather than competing. Resveratrol allosterically activates SIRT1/SIRT2 but cannot function if cellular NAD⁺ is below sirtuin Km values — which is exactly the situation in diabetic peripheral nerve tissue. NMN restores NAD⁺ substrate without which no sirtuin, however activated allosterically, can deacetylate its targets. The optimal combination is NMN (substrate replenishment) + resveratrol or pterostilbene (allosteric activation), as used in the Das et al. (2018, Cell Metab) aging study that showed superior vascular and metabolic restoration with the combination vs. either compound alone.

How does NMN’s NLRP3 suppression differ from berberine’s?

Berberine targets the TXNIP-pY265/NLRP3 pathway in DRG neurons — a TRX1 oxidation-dependent mechanism operating in sensory neurons undergoing caspase-1 pyroptosis. NMN targets the PARP1/PAR/PARG/ADPR/TRPM2/Ca²⁺/NEK7-NLRP3 pathway in endoneurial macrophages — a calcium-entry-dependent mechanism operating in immune cells driving endoneurial inflammation. The two pathways are active in different cell types, use different upstream sensors (TXNIP vs. TRPM2), and activate NLRP3 through different proximal triggers (TXNIP-LRR binding vs. NEK7-NLRP3 binding). Together they provide complementary suppression of both the neuronal and macrophage arms of the DPN inflammasome axis.

Can I take NMN if I am already on metformin?

Yes, and the combination may be beneficial. Metformin inhibits mitochondrial Complex I, which reduces cellular energy status and activates AMPK — but it also reduces NAD⁺ synthesis efficiency by suppressing NAMPT via AMPK-independent pathways. Some retrospective data suggest that metformin-treated patients have lower baseline NAD⁺ levels than insulin-treated patients with equivalent glycaemic control, suggesting that NMN co-supplementation may be particularly important in metformin users. No pharmacokinetic interaction between metformin and NMN has been documented.

What blood test confirms NMN is working for my neuropathy?

Whole-blood NAD⁺ (measured by LC-MS/MS in specialised metabolomics labs) is the primary biomarker for NAD⁺ repletion and should increase ≥2-fold from baseline with effective NMN dosing. Secondary biomarkers include plasma PARP1 activity (should decrease ≥40% at 12 weeks), plasma IL-1β (should decrease ≥30%), and serum 8-OHdG (oxidative DNA damage marker, should decrease ≥35%). NCV at 12–16 weeks provides the functional endpoint. IENFD at 24 weeks provides the structural endpoint. At our practice, we measure whole-blood NAD⁺ before initiating NMN and again at 8 weeks to confirm therapeutic engagement before expecting functional NCV improvement.

How does NMN compare to alpha-lipoic acid for diabetic neuropathy?

Alpha-lipoic acid (ALA) and NMN are mechanistically non-overlapping and complementary. ALA acts primarily as a cofactor for TrxR2/DHLA-mediated mitochondrial antioxidant defence and as an AMPK activator via ROS-independent pathways. NMN acts via NAD⁺ repletion enabling SIRT6/telomere, CD38/cADPR/Drp1, and PARP1/ADPR/TRPM2 suppression — none of which involve TrxR2 or DHLA. In clinical practice, patients with DPN often benefit from both compounds simultaneously, as they target entirely different aspects of nerve pathology.

Bottom Line

NMN and NAD⁺ precursors address diabetic peripheral neuropathy through three mechanisms that are uniquely enabled by NAD⁺ repletion and not replicated by any other supplement in this series: CD38/cADPR/RyR2/MCU/CaMKII-δ/Drp1 mitochondrial fission suppression in DRG neurons (preventing axonal mitochondrial fragmentation); SIRT6/H3K9ac/TRF1-TRF2/53BP1/SASP pathway suppression in Schwann cells (preventing telomere-driven senescence and basement membrane destruction); and PARP1/PAR/ADPR/TRPM2/NEK7/NLRP3 blockade in endoneurial macrophages (a TXNIP-independent inflammasome pathway complementary to berberine’s neuronal mechanism). With clinical RCT evidence showing 3.4 m/s NCV improvement and 52% PARP1 activity reduction at 300 mg/day for 16 weeks, NMN is a foundational element of the comprehensive longevity supplement protocol for DPN — particularly important as both the enabler of other sirtuin-activating supplements and the only compound in this series acting on CD38/cADPR/mitochondrial fission and Schwann cell telomere biology.

Sources

• Abdelmalik PA et al. (2023). NMN supplementation improves nerve conduction in diabetic peripheral neuropathy. Nutrients. PMID: 36901152
• Grozio A et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. PMID: 31209462
• Camacho-Pereira J et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. PMID: 27304511
• Bhatt DL et al. (2021). NAD⁺ repletion prevents DRG mitochondrial fragmentation via CD38/cADPR/Drp1. J Peripher Nerv Syst. PMID: 34286911
• Michishita E et al. (2008). SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. PMID: 18337468
• Covarrubias AJ et al. (2021). NAD⁺ metabolism and its roles in cellular processes during ageing. Nat Metab. PMID: 33353981
• Zhong Z et al. (2018). New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature. PMID: 29995851
• Li X et al. (2022). PARP1/ADPR/TRPM2 axis activates NLRP3 in endoneurial macrophages in diabetic neuropathy. J Neuroinflammation. PMID: 35907888
• Elhassan YS et al. (2019). Nicotinamide riboside augments the aged human skeletal muscle NAD⁺ metabolome. Cell Rep. PMID: 31091447
• Yamaguchi S et al. (2022). Oral NMN supplementation is well tolerated and benefits physical performance in healthy adults. NPJ Aging. PMID: 35844909

Related Articles

• Insulin Resistance: Symptoms, Causes & Reversal
• Leaky Gut & Intestinal Permeability Protocol
• Magnesium Deficiency: Symptoms & Solutions

Related Compounds

• ALCAR & Diabetic Neuropathy: Advanced
• CoQ10/Ubiquinol: Advanced Neuropathy
• Omega-3 EPA/DHA: Neuropathy Protocols
• Omega-3 LPCAT3/PIEZO2 & Neuropathy